House committee substitute to the 1st edition makes the following changes.
Amends new GS 130A-453.34 as follows. Removes from the definition of intentionally added DEHP DEHP that is an intentional breakdown product of an added chemical. Adds and defines the term unintentionally added DEHP as DEHP in an intravenous solution container or intravenous tubing product that is not used for functional or technical effect on the product. 
Amends proposed GS 130A-453.35 by adding that a person or entity, due to pending USFDA approval for the DEHP-free intravenous solution container or due to the manufacturer not having adequate equipment to manufacture the DEHP-free intravenous solution container, must meet the requirements of the statute concerning the solution containers by January 1, 2032, if: (1) they notified their NC customers, no later than October 1, 2025, that it commenced development of the DEHP-free intravenous solution container to meet the statute's requirements and (2) it provides notice to its customers and posts to its website, by January 1, 2028, that it will not meet the January 1, 2030 deadline.

Statutes affected:
Filed: 130A-22
Edition 1: 130A-22
Edition 2: 130A-22